


This document is made available through the declassification efforts
and research of John Greenewald, Jr., creator of:

The Black Vault



The Black Vault is the largest online Freedom of Information Act (FOIA)
document clearinghouse in the world. The research efforts here are
responsible for the declassification of MILLIONS of pages
released by the U.S. Government & Military.

Discover the Truth at: <http://www.theblackvault.com>



2-3 MAR 1970

MEMORANDUM FOR: [REDACTED]

SUBJECT : Follow-on Contract No. [REDACTED] with the [REDACTED]

1. This memorandum contains a recommendation for your approval. The recommendation is contained in Paragraph 7.

2. The research program detailed in the accompanying proposal is part of the Materials Analysis Project. The work, with one exception, is essentially a continuation of our present level of effort to identify pharmacological agents with new and unusual effects. The exception is the inclusion of two preclinical subacute animal studies required by the Food and Drug Administration and by Edgewood on any chemical compound before it can be clinically evaluated. These studies will be done on compounds expected to be selected in committee during the term of this contract.

3. [REDACTED] the contractor for this follow-on research, has during the past twelve months screened approximately 120 new compounds. This is twice the number screened the previous year. Potentially useful compounds detected earlier in the program have now been evaluated in the newly established advanced screening tests. These tests are now fully operative and are supplying additional data which will enable us to select certain compounds for preclinical subacute animal studies. A back-log of over 4,000 compounds has now been acquired for this screening program and databanked for future screening purposes. As a result of this large back-log, itself composed of specially developed compounds, the primary and secondary screening effort will be further increased with respect to numbers of compounds tested and at the same time made more discriminative and selective. No special problems or technical difficulties are anticipated in the program. The contractor will deliver detailed toxicological and pharmacological data on each compound tested on a quarterly basis as well as a comprehensive final report.

[REDACTED]

Page 2

[REDACTED]

4. The proposed work will cover a period of twelve months and will cost approximately [REDACTED] the logical choice to continue this work because of their superior performance in the past and because of their unique access to compounds essential to the program. Coordination has been affected with [REDACTED] and Edgewood Arsenal Research Laboratories, U. S. Army (Dr. [REDACTED])

5. This project will have a major impact on the Agency's potential for controlling human performance and for defense against exploitation of key national personnel by hostile intelligence services. Follow-on research can, therefore, be expected to continue at the same general level of effort.

6. As in the past, this research will be classified [REDACTED] Association with the Agency will be classified SECRET. The reports will be classified SECRET. The project monitor will be Dr. [REDACTED] extension [REDACTED]

7. The [REDACTED] requests approval of establishing a follow-on contract to contract No. [REDACTED] Task Order No. 3 with the [REDACTED] The work will cover a period of twelve months at a cost of approximately [REDACTED]

[REDACTED]

APPROVED:

[REDACTED]

28 Nov '70

Date